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Summary 
The potencies of several opioid agonists are reduced in diabetic 
animals and in animals made hyperglycemic via injections of glucose. In 
this report we examined the effects of streptozotocin-induced diabetes on 
the feeding responses to centrally administered opioid agonists with 
differing receptor selectivities. The selective mu receptor agonist Tyr-D- 
Ala-Gly-(Me)Phe-Gly-ol (DAGO) caused a larger increase in intake in 
diabetic rats than in controls. In both groups feeding responses were 
greater on the fourth day of daily injections than on the first day. The 
delta receptor agonist [D-Ser2,Leu5]-enkephalin-Thr 6 (DSLET) 
stimulated intake in controls but not in diabetics. However, the elevated 
baseline and large variability in intake of the diabetics in this experiment 
prevent drawing a conclusion on diabetes-induced changes in the 
potency of this peptide. No differences between controls and diabetics 
were apparent in the feeding responses to U50,488H, a selective kappa 
receptor agonist. These data suggest that diabetes may differentially 
affect the classes of opioid receptors or the binding of ligands to these 
receptors. 
Opioid agonists and antagonists cause increases and decreases, respectively, 
in food and water intake, and endogenous opioid peptides are thought to contribute to 
the regulation of appetite (see I, 2 for reviews). Since some effects of opiates are 
altered by the glycemic state of the animal, we examined the effects of chemically 
induced diabetes on the feeding responses to central administration of selective 
opioid agonists. 
Simon and Dewey (3) and Simon et al. (4) reported that opiate-induced 
analgesia was decreased in mice made diabetic by treatment with streptozotocin 
(STZ), as well as in mice given injections of hypertonic dextrose or fructose. 
Conversely, hypoglycemic mice were more sensitive to the antinociceptive effects of 
morphine (3). Diabetic mice also developed less physical dependence to morphine 
0024-3205/89 $3.00 + .00 
Copyright (c) 1989 Pergamon Press plc 
32 Opioid Induced Feeding in Diabetes Vol. 45, No. i, 1989 
than non-diabetic mice (5). Similarly, intraperitoneal injections of glucose blocked the 
increase in tail skin temperature observed during naloxone-precipitated morphine 
withdrawal (6). 
I__n vitro, the inhibitory effect of normorphine on electrically-induced contractions 
of the guinea pig ileum and mouse vas deferens were reduced by the addition of 
glucose to the bathing medium (7). This finding suggests that the effect of diabetes on 
in vivg responses to opiates is due to elevated glucose levels rather than to some 
other changes associated with diabetes. This possibility is supported by the work of 
Brase et al. (8), which demonstrated that glucose decreases high affinity binding of 
naloxone in mouse brain membranes. However, these authors indicate that 
decreased binding affinity cannot completely explain the in vivo effects of 
hyperglycemia on opioid responses; they suggest that glucose metabolism, glucose- 
endogenous opioid interactions or an interaction of glucose with ion transport 
mechanisms may also be important. 
Recently, we reported that repeated daily injections of morphine caused a 
greater weight loss in controls than in STZ-diabetic rats (9). Similarly, daily morphine 
injections reduced feed efficiency to a greater extent in controls than in diabetic rats. 
Thus, although it is unclear why morphine increases short-term intake (9-13) yet 
decreases total daily intake and rate of body weight gain when given in repeated daily 
injections (9,11,14,15), the attenuated effects of long-term morphine treatment in 
diabetic rats are consistent with studies cited above. 
The opiate antagonist naloxone has been shown to cause a decrease in food 
intake in a number of species, including man (see 1). In short term feeding trials, STZ- 
treated diabetic rats appeared to be less sensitive to naloxone than controls (16). 
However, when the rats were tested in a novel environment, diabetic rats were more 
sensitive to naloxone than control animals. Similarly, genetically obese hyper- 
glycemic mice and streptozotocin-induced diabetic mice were more sensitive to 
naloxone than lean controls when tested in a novel environment (17). 
The aforementioned in vivo studies have relied on peripheral administration of 
agonists and antagonists. In the experiments described here, we injected selective 
opioid agonists into the lateral cerebral ventricle of normal rats and rats made diabetic 
by intravenous injection of STZ. The peptides Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAGO) 
and [D-Ser2,Leu5]-enkephalin-Thr 6 (DSLET) were used as selective agonists of mu 
and delta opioid receptors, respectively (18,19). Both peptides have been shown to 
stimulate food intake when injected intracerebroventricularly (icv) (20,21). We also 
tested U-50,488H, a selective kappa agonist (22), which has been found to increase 
intake when injected subcutaneously (23,24) or icv (unpublished observations). 
Methods 
DAGO, DSLET and U50,488H were tested in three separate experiments. Male 
Sprague-Dawley rats were housed individually in stainless steel cages and given food 
and water ad tibitum. Lights were on from 7 AM to 7 PM. In each experiment, 
approximately one half of the animals were made diabetic by the injection of 65 mg/kg 
of streptozotocin into the tail vein. To verify that STZ-treated rats were hyperglycemic, 
0.1 ml blood samples were taken from a tail vein 4-6 days later and blood glucose was 
determined by a glucose oxidase kit (Sigma Chemical Co., St. Louis, MO). All diabetic 
rats had blood glucose levels greater than 400 mg/dl (619 + 12 mg/dl). Five to nine 
days after STZ treatments, a stainless steel guide cannula (20 gauge) was implanted 
into the lateral cerebral ventricle of each rat. Coordinates for the tip of the guide 
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cannula were 1 mm posterior and 1.5 mm lateral to bregma and 3.5 mm ventral to the 
surface of the skull. At least 7 days were allowed for recovery from this procedure. 
In the first experiment, STZ-treated and control rats were given 
intracerebroventricular (icv) injections of 0 (saline), 1, 3 or 10 nmol of DAGO. Thus, 
there were a total of 8 groups (2 glycemic states x 4 drug doses), with 4-5 rats per 
group. All injections were given in a 5 p.I volume through a 25 gauge cannula which 
extended 1 mm beyond the tip of the guide cannula. Immediately after injections, rats 
were returned to their home cages and a pre-determined amount of laboratory chow 
was placed in the floor of each cage. Intake was determined by weight 2, 4 and 6 
hours after injection and was corrected for spillage at each measurement. We have 
found these times and the range of doses tested to be adequate to characterize the 
feeding responses to a number of centrally or systemically administered opioid 
agonists (12,20,21 and unpublished observations). To assess the effects of repeated 
opioid administration, these procedures were repeated in an identical manner on the 
following three days, with each rat receiving the same dose on all four days. 
Data were analyzed with a three-factor analysis of variance (ANOVA). A 
separate ANOVA was performed at each measurement (2, 4 and 6 hours). Drug dose 
and diabetic state were between-groups factors, and the trials on Days 1 and 4 were 
treated as a repeated-measures factor. Data from Days 2 and 3 were not included in 
this analysis. Within each day and diabetic state, mean intakes of the groups receiving 
DAGO were compared to the saline-injected group with Dunnett's test. 
In the second experiment, DSLET was tested in naive rats with procedures and 
doses identical to those described above for DAGO (n = 6-11 per group). In the third 
experiment, the kappa agonist U50,488H was tested in naive rats with procedures 
identical to those in the first two experiments with the exception that the doses used 
were 0 (saline), 21,64 and 215 nmol (n = 6-10 per group). 
DAGO and DSLET were purchased from Sigma Chemical Company (St. Louis, 
MO) and U50,488H was purchased from the Upjohn Company (Kalamazoo, MI). 
Results 
Feeding Trials: To simplify presentation of the results from the DAGO trials, only 
four hour cumulative intake data are represented graphically. For DSLET and 
U50,488H, only 2 hour intakes are shown. In our laboratories, we have found that the 
maximum effects of these agonists are generally observed in these time periods 
(20,21 and unpublished observations). 
DAGO: A three-factor ANOVA indicated significant main effects of DAGO at 2, 4 
and 6 hours, of diabetes at 4 and 6 hours and of treatment day at 2 and 4 hours. 
Furthermore, the interaction between DAGO and diabetes was significant at 6 hours 
and approached the 
significance criterion of p < .05 at 4 hours (p = .058). None of the interactions involving 
treatment day were significant. On Day 1, none of the doses increased intake in 
controls at 2, 4 or 6 hours. In diabetics, the 10 nmol dose significantly increased 4 and 
6 hour intake. Intakes of the groups receiving 1 and 3 nmols were elevated but not 
significantly greater than the saline-injected group. Four hour intake data are rep- 
resented in Figure 1. 
Both diabetics and controls were more responsive to DAGO on Day 4 than on 
Day 1. All three doses increased 2 hour intake in controls, and 4 hour intake was 
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increased by the 1 and 10 nmol doses. Intake in the 3 nmol group was elevated but 
was approximately 0.2 g less than that required for statistical significance. In diabetics, 
the 10 nmol dose increased 2 hour intake, and all three doses increased 4 and 6 hour 
intake. Although a similar dose range was effective in both groups, the increases in 
intake were greater in diabetics than controls. There was no significant interaction 
between treatment day and diabetes. 
DSLET: There were significant main effects of diabetes and DSLET at the 2, 4 
and 6 hour measurements (p < .05). Generally, DSLET was more effective at 
increasing intake in control rats than in diabetics. This is supported by a significant 
diabetic X DSLET interaction at 2 and 6 hours (this interaction approached 
significance at 4 hours, p = .086). On Day 1, the 10 nmol dose stimulated 2 hour 
intake in controls (Figure 2); the increase was not significant at 4 or 6 hours. In 
diabetic animals, no significant increases above baseline intake were observed at any 
measurement. However, an unusually high baseline and large variability in the 
diabetic group makes it difficult to draw conclusions about feeding responses to 
DSLET. 
The overall Day effect (Day 1 vs. Day 4) was not significant at any 
measurement, although it approached the significance criterion at 6 hours (p = .055). 
The interaction of DSLET and treatment day was significant at 4 and 6 hours and 
approached significance at 2 hours (p = .056). As these interactions would suggest, 
the feeding responses to DSLET were slightly greater after repeated injections, at 
least in controls. The effect of the 10 nmol dose was more prolonged on Day 4, where 
intake was increased at 2, 4 and 6 hours. On Day 1, the increase was not significant 
beyond the 2 hour measurement. While none of the doses increased intake in 
diabetic rats on Day 1, the 1 nmol dose did significantly increase 6 hour intake on Day 
4 (not shown). That this dose (but not the higher ones) would be effective was 
unexpected. However, as the 2 hour results in Figure 2 illustrate, the diabetic rats in 
this experiment were characterized by a large variability in feeding responses. 
U50.488H; A three-factor ANOVA indicated significant main effects of 
U50,488H at 2 and 4 hours; this effect approached significance at 6 hours (p = .084). 
The main effect of treatment day was significant at 2, 4 and 6 hours, whereas the 
diabetic main effect was significant only at 6 hours (all p's < .05). The interaction 
between treatment day and diabetes was significant at 6 hours and approached 
significance at 4 hours (p = .053). 
No large differences in responses to U50,488H were observed between 
diabetics and controls (Figure 3). This is supported by the lack of significant 
interactions between diabetes and U50,488H at 2 and 4 hours (this interaction 
approached significance at 6 hours, p = .071). On Day 1, the highest dose tested (215 
nmol) caused a significant increase in the intake of controls at 2, 4 and 6 hours. In 
diabetics, this dose increased 2 and 4 hour intake; these increases were smaller than 
those observed in non-diabetic rats given this dose. Intake of the diabetic group 
receiving the lowest dose tested (21 nmols) fell just short of significance at 2 hours but 
was significantly increased at 4 and 6 hours. 
Repeated injections did not increase the effectiveness of U50,488H. This is 
supported by the lack of significant interaction between U50,488H and treatment day. 
In fact, while the intakes of the groups receiving 215 nmols were elevated on Day 4, 
the difference was just short of significance for both controls and diabetics. As Figure 
3 indicates, however, baseline intakes for the two groups on Day 4 were unexpectedly 
higher than on Day 1. 
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Fig. 1 
A. Four hour food intake (mean + SEM, in grams) for non-diabetic and diabetic 
rats after the first icv injection of the mu agonist DAGO. B. Food intake as in 
(A) on the fourth day of daily icv injections of DAGO (n = 4 or 5 per group; *p < 
.05, Dunnett's test, one-tailed). 
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Fig. 2 
A. Two hour food intake (mean + SEM, in grams) for non-diabetic and diabetic 
rats after the first icv injection of the delta agonist DSLET. B. Food intake as in 
(A) on the fourth day of daily icv injections of DSLET (n = 6 to 11 per group; *p < 
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A. Two hour food intake (mean + SEM, in grams) for non-diabetic and diabetic 
rats after the first icv injection of the kappa agonist U50,488H. B. Food intake 
as in (A) on the fourth day of daily icv injections of U50,488H (n = 6 to 10 per 
group; *p < .05, Dunnett's test, one-tailed). 
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Discussion 
These experiments were performed to determine whether streptozotocin- 
induced diabetes altered the feeding response to centrally administered opioid 
agonists. As discussed in the Introduction, some responses to opiates are altered in 
diabetic animals, and the changes are thought to be due to hyperglycemia. The recent 
report by Brase et al. (8) suggests that glucose decreases opioid receptor binding 
affinity in the brain. The diabetic condition would provide an elevated glucose en- 
vironment in the brain, as changes in serum glucose level are generally reflected in 
brain glucose levels (3). 
Based on in vivo and in vitro results from other laboratories, one would predict 
an attenuation of opioid-induced feeding in diabetic rats (3-8). However, the present 
study does not support this prediction. The feeding response to DAGO was greater in 
STZ-treated diabetic rats than in controls. In contrast, the feeding response to 
U50,488H was not markedly affected by diabetes. Because DAGO and U50,488H act 
primarily at different receptors, these results suggest the possibility that the various 
receptors (or binding to these receptors) are differentially affected by diabetes. 
The effect of diabetes on feeding responses to DSLET is not clear. This may be 
due in part to the large variability in feeding responses and fluctuations in baseline 
intake. For example, the intake of the diabetic rats given the 3 nmol dose was much 
lower than that of rats given a higher or lower dose. Also, the 2 hour intake of saline- 
injected rats (1.5 g) was greater than the intake of control (non-diabetic) rats which 
received the 10 nmol dose (1.4 g), which was significantly increased above the control 
baseline. Comparing groups with different baselines is problematic in the study of 
opioid-induced feeding, since it has been shown that opioids actually decrease intake 
when intake is normally elevated, e.g., after food deprivation or during the nocturnal 
period of the light-dark cycle (12,13,25). 
Another complication in the interpretation of the U50,488H results is the 
tendency for baseline intake to increase after repeated trials. For both diabetics and 
controls, baselines increased from under 0.2 g on Day 1 to 1.1 - 1.6 g on Day 4. This 
increase was not observed in the DAGO and DSLET experiments, and cannot be 
attributed to differences in the agonists, since the control groups in all three 
experiments received only saline injections. Although we have observed this effect in 
other studies involving repeated testing of animals (9,20), the present results, along 
with unpublished observations, suggest that this shift in baseline is not consistent 
across experiments. The cause of the shift is not known, and we are not aware of any 
studies that have directly addressed this problem. 
That the feeding responses to some opioid agonists are often not apparent until 
2-4 hours after injection may be due to other opioid effects, such as sedation or 
catalepsy, which would interfere with feeding. In the dose range tested, DAGO 
produces a clear cataleptic state which precedes the feeding response and dissipates 
within 1-2 hours. We and others have noted that after repeated opioid injections, the 
feeding responses occur earlier and/or increase in magnitude (12,26-30). This effect 
of chronic or repeated exposure has also been noted for opiate-induced increases in 
temperature and locomotor activity (31,32). In the present report, the response to 
DAGO was greater on Day 4 than on Day 1. This also occurred with DSLET, at least in 
non-diabetic rats. In relation to feeding, this effect has been explained as being due to 
the development of tolerance to certain effects of opioids that interfere with feeding 
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behavior, thereby "unmasking" the feeding response such that it is greater and 
appears earlier (2,12,26). 
It is possible that the enhanced response to DAGO observed in diabetics is 
simply a consequence of decreased opioid effects on other systems which might 
interfere with feeding. The present experiments cannot directly address this 
possibility, since other behavioral effects of the agonists were not measured. 
However, this interpretation would be in partial agreement with other reports of 
decreased sensitivity to opioid agonists in diabetic animals. It leaves unexplained, 
however, why the actual feeding response is not also attenuated in diabetics. 
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